On May 1, 2015 Sorrento Therapeutics reported that its fully owned subsidiary, IGDRASOL, has acquired exclusive distribution rights from Samyang Biopharmaceuticals ("Samyang"), a South Korean corporation, to Cynviloq (marketed as Genexol-PM in South Korea) in South America (Filing, 8-K, Sorrento Therapeutics, MAY 1, 2015, View Source [SID:1234503560]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!